JP2021523913A5 - - Google Patents
Info
- Publication number
- JP2021523913A5 JP2021523913A5 JP2020564167A JP2020564167A JP2021523913A5 JP 2021523913 A5 JP2021523913 A5 JP 2021523913A5 JP 2020564167 A JP2020564167 A JP 2020564167A JP 2020564167 A JP2020564167 A JP 2020564167A JP 2021523913 A5 JP2021523913 A5 JP 2021523913A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023183225A JP7680514B2 (ja) | 2018-05-16 | 2023-10-25 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862672299P | 2018-05-16 | 2018-05-16 | |
| US62/672,299 | 2018-05-16 | ||
| PCT/US2019/032582 WO2019222449A1 (en) | 2018-05-16 | 2019-05-16 | Protein binding nkg2d, cd16 and a fibroblast activation protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023183225A Division JP7680514B2 (ja) | 2018-05-16 | 2023-10-25 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523913A JP2021523913A (ja) | 2021-09-09 |
| JP2021523913A5 true JP2021523913A5 (enExample) | 2022-05-20 |
| JP7494129B2 JP7494129B2 (ja) | 2024-06-03 |
Family
ID=68540990
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564167A Active JP7494129B2 (ja) | 2018-05-16 | 2019-05-16 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
| JP2023183225A Active JP7680514B2 (ja) | 2018-05-16 | 2023-10-25 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023183225A Active JP7680514B2 (ja) | 2018-05-16 | 2023-10-25 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210363261A1 (enExample) |
| EP (1) | EP3793605A4 (enExample) |
| JP (2) | JP7494129B2 (enExample) |
| KR (1) | KR20210010508A (enExample) |
| CN (1) | CN112423788A (enExample) |
| AU (2) | AU2019271263A1 (enExample) |
| BR (1) | BR112020023299A2 (enExample) |
| CA (1) | CA3100234A1 (enExample) |
| MX (1) | MX2020012273A (enExample) |
| SG (1) | SG11202011139YA (enExample) |
| WO (1) | WO2019222449A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| EP4284518A4 (en) | 2021-01-27 | 2025-02-19 | Georgetown University | Fibroblast activation protein modulation to alter immune cell migration and tumor infiltration |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| JP2025502189A (ja) * | 2022-01-11 | 2025-01-24 | アディマブ， エルエルシー | 優先的ｃｈ３ヘテロ二量体化のために操作されたバリアントｃｈ３ドメイン、それを含む多重特異性抗体、及びその作製方法 |
| EP4311557A1 (en) * | 2022-07-26 | 2024-01-31 | Oncomatryx Biopharma, S.L. | Fap-targeted antibody-drug conjugates |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| WO2025244097A1 (ja) * | 2024-05-23 | 2025-11-27 | オプティアム・バイオテクノロジーズ株式会社 | 改良型抗ＦＡＰα－キメラ抗原受容体 |
| CN119265201A (zh) * | 2024-08-23 | 2025-01-07 | 中国人民解放军海军军医大学第一附属医院 | 编码基因、蛋白、表达il-15的nkg2dl-fap双靶点car-nk细胞及其构建方法和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1934260B1 (en) * | 2005-10-14 | 2017-05-17 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| WO2009077483A1 (en) * | 2007-12-14 | 2009-06-25 | Novo Nordisk A/S | Antibodies against human nkg2d and uses thereof |
| US9273136B2 (en) * | 2008-08-04 | 2016-03-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fully human anti-human NKG2D monoclonal antibodies |
| TW201109438A (en) | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| RU2583876C2 (ru) * | 2009-08-17 | 2016-05-10 | Роше Гликарт Аг | Иммуноконъюгаты направленного действия |
| PE20171512A1 (es) * | 2010-08-13 | 2017-10-20 | Roche Glycart Ag | Anticuerpos anti-fap |
| CN104203981A (zh) * | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| GB201402006D0 (en) * | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| WO2016115274A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| JP6840682B2 (ja) * | 2015-06-23 | 2021-03-10 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 多重特異的抗原結合タンパク質 |
| US20190031785A1 (en) | 2016-01-13 | 2019-01-31 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| JP2018035137A (ja) * | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| CN110944651A (zh) * | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| KR20210029298A (ko) * | 2017-08-16 | 2021-03-15 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16, 및 egfr, ccr4 또는 pd-l1에 결합하는 단백질 |
-
2019
- 2019-05-16 SG SG11202011139YA patent/SG11202011139YA/en unknown
- 2019-05-16 WO PCT/US2019/032582 patent/WO2019222449A1/en not_active Ceased
- 2019-05-16 CA CA3100234A patent/CA3100234A1/en active Pending
- 2019-05-16 CN CN201980047481.2A patent/CN112423788A/zh active Pending
- 2019-05-16 JP JP2020564167A patent/JP7494129B2/ja active Active
- 2019-05-16 AU AU2019271263A patent/AU2019271263A1/en not_active Abandoned
- 2019-05-16 EP EP19803947.1A patent/EP3793605A4/en active Pending
- 2019-05-16 US US17/055,792 patent/US20210363261A1/en not_active Abandoned
- 2019-05-16 BR BR112020023299-8A patent/BR112020023299A2/pt not_active Application Discontinuation
- 2019-05-16 KR KR1020207035733A patent/KR20210010508A/ko not_active Ceased
- 2019-05-16 MX MX2020012273A patent/MX2020012273A/es unknown
-
2023
- 2023-10-25 JP JP2023183225A patent/JP7680514B2/ja active Active
-
2026
- 2026-02-26 AU AU2026201454A patent/AU2026201454A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023509448A5 (enExample) | ||
| JP2021534096A5 (enExample) | ||
| JP2025111463A5 (enExample) | ||
| JP2020522474A5 (enExample) | ||
| JP2022061993A5 (enExample) | ||
| JP2021035388A5 (ja) | Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２またはクローディン−１８．２を標的にする多重特異性結合タンパク質 | |
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| JP2023123726A5 (enExample) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2020521448A5 (enExample) | ||
| JP2019536430A5 (enExample) | ||
| JP2022507487A5 (enExample) | ||
| JP2020508997A5 (enExample) | ||
| JP2021522162A5 (enExample) | ||
| JP2021533159A5 (enExample) | ||
| JP2013527761A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| JP2023516004A5 (enExample) | ||
| JP2018507188A5 (enExample) | ||
| JP2021522347A5 (enExample) | ||
| JP2022513043A5 (enExample) | ||
| RU2019129511A (ru) | Белки, связывающие gd2, nkg2d и cd16 | |
| JP2024504390A5 (enExample) | ||
| JP2024016024A5 (enExample) | ||
| JP2023529842A5 (enExample) |